Drug Trial Radar · NCT05384977
Mass Balance Study of NV-5138 in Healthy Male Subjects
Last checked: Nov 19, 2026Latest source record: May 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Nov 11, 2021
Primary completion
Dec 9, 2021
Study completion Dec 9, 2021
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the mass balance and routes of excretion of total radioactivity after a single oral dose of 1600 mg \[14C\]-NV-5138.
Conditions
- Healthy Volunteers
Interventions
[14C]-NV-5138Drug
Single dose, given as oral solution, 1600 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative total radioactivity in urine and faecesTime frame: urine and fecal samples up to 168 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Ruddington, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.